My laboratory uses a multidisciplinary approach that combines computational and experimental laboratory techniques. I use genetics, transcriptomics, and drug perturbations from disease-relevant cell types to prioritize potential drugs for neurodegenerative diseases. Then, computationally nominated drugs are validated in induce pluripotent cell-(iPSC) derived models of these diseases.